Canopy Growth (CGC) Stock Price, News & Analysis

Company Overview

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc., Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments. Its medical division supplies pharmaceutical-grade cannabis to patients in Canada and select international markets via Spectrum Therapeutics. On the adult-use side, brands like Tokyo Smoke and Doja focus on lifestyle-oriented products and retail experiences. Canopy additionally conducts research into cannabinoids and product formulations to expand its portfolio and address emerging consumer preferences.

Founded in 2013 by Bruce Linton, Chuck Rifici and Neil Belot, Canopy Growth quickly grew through organic expansion and strategic acquisitions. In March 2020, the company appointed David Klein as Chief Executive Officer, entrusting him with the integration of acquired assets and execution of a global growth strategy. Klein brought extensive consumer packaged goods experience, having previously led Constellation Brands’ beverage business in Canada.

Canopy Growth serves markets in Canada and maintains operations or partnerships across Europe, Australia and Latin America. The company has also established a presence in the United States through joint ventures and investments, positioning itself to capitalize on the evolving regulatory landscape. With a focus on innovation, international expansion and brand development, Canopy Growth aims to maintain its leadership in the rapidly changing cannabis industry.

Key Stats

• Today's Range: $1.38 to $1.48
• 50-Day Range: $1.02 to $1.88
• 52-Week Range: $0.77 to $5.80
• Volume: 19.04 million shs
• Average Volume: 31.51 million shs
• Market Capitalization: $350.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Canopy Growth Stock Analysis - MarketRank™

Canopy Growth scored higher than 23% of companies evaluated by MarketBeat, and ranked 846th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Canopy Growth.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Canopy Growth are expected to grow in the coming year, from ($2.81) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Canopy Growth is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Canopy Growth is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Canopy Growth has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.28% of the float of Canopy Growth has been sold short.

Short Interest Ratio / Days to Cover

Canopy Growth has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Canopy Growth has recently decreased by 22.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Canopy Growth does not currently pay a dividend.

Dividend Growth

Canopy Growth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 0.0 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

9.28% of the float of Canopy Growth has been sold short.

Short Interest Ratio / Days to Cover

Canopy Growth has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Canopy Growth has recently decreased by 22.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.08

News Sentiment

Canopy Growth has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Canopy Growth this week, compared to 9 articles on an average week.

Search Interest

33 people have searched for CGC on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.

MarketBeat Follows

6 people have added Canopy Growth to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Canopy Growth insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,915.00 in company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Canopy Growth is held by insiders.

Percentage Held by Institutions

Only 3.33% of the stock of Canopy Growth is held by institutions.

CGC Stock Analysis - Frequently Asked Questions

How have CGC shares performed this year?

Canopy Growth's stock was trading at $2.74 at the start of the year. Since then, CGC stock has decreased by 46.7% and is now trading at $1.46.

How were Canopy Growth's earnings last quarter?

Canopy Growth Corporation (NASDAQ:CGC) announced its quarterly earnings results on Friday, August, 8th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The company earned $52.98 million during the quarter, compared to analysts' expectations of $64.98 million. Canopy Growth had a negative net margin of 155.76% and a negative trailing twelve-month return on equity of 89.93%.
Read the conference call transcript.

When did Canopy Growth's stock split?

Canopy Growth's stock reverse split on Wednesday, December 20th 2023.The 1-10 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Canopy Growth's major shareholders?

Canopy Growth's top institutional investors include Tidal Investments LLC (2.45%), SBI Securities Co. Ltd. (0.26%), Simplex Trading LLC and Two Sigma Securities LLC (0.14%). Insiders that own company stock include Christelle Gedeon, Judy Eun Joo Hong, Thomas Carlton Stewart, Theresa Yanofsky, David Angelo Lazzarato and Willy Kruh.
View institutional ownership trends.

How do I buy shares of Canopy Growth?

Shares of CGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Canopy Growth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Canopy Growth investors own include NVIDIA (NVDA), Meta Platforms (META), Alibaba Group (BABA), Micron Technology (MU), GE Aerospace (GE), BMO Capital Markets () and Stifel Nicolaus ().

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/08/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGC
• CIK: 1737927
• Web: www.canopygrowth.com
• Phone: (855) 558-9333
• Fax: N/A
• Employees: 3,150
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$429.86 million
• Net Margins: -155.76%
• Pretax Margin: -157.48%
• Return on Equity: -89.93%
• Return on Assets: -44.24%

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 3.07
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $225.65 million
• Price / Sales: 1.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.90 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 239,850,000
• Free Float: 239,465,000
• Market Cap: $350.18 million
• Optionable: Optionable
• Beta: 0.76